Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107536 | 0.92 | POLB (0.59) | POLBROCK2ROCK1CARM1PRMT6 | |
| SCHEMBL7110318 | 0.83 | POLB (0.58) | POLBROCK2ROCK1CARM1PRMT6 | |
| SCHEMBL7108431 | 0.80 | KDM4E (0.44) | ROCK2ROCK1CARM1PRMT6CCR2 | |
| SCHEMBL7110809 | 0.77 | CARM1 (0.62) | ROCK2ROCK1CARM1PRMT6CCR2 | |
| SCHEMBL7108846 | 0.77 | SLC6A2 (0.56) | SIGMAR1MAOB | |
| SCHEMBL7108255 | 0.76 | HRH3 (0.50) | CARM1PRMT6HRH3SIGMAR1 | |
| SCHEMBL2798023 | 0.75 | SIGMAR1 (0.63) | POLBHRH3SIGMAR1 | |
| SCHEMBL7104325 | 0.75 | POLB (0.43) | POLBROCK2ROCK1CARM1PRMT6 | |
| SCHEMBL2794926 | 0.74 | HTR1A (0.69) | HRH3SIGMAR1 | |
| SCHEMBL6125214 | 0.73 | POLB (1.00) | POLBROCK2ROCK1FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | claimed |
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | disclosed |
| US-6448270-B1 | BICYCLIC HETEROARYL ACETYLENES; NEUROPROTECTIVE AGENTS; STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTIC INDUCED HEARING LOSS, MIGRAINES, CHRONIC PAIN, GLAUCOMA | WARNER-LAMBERT COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6130234-A | 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0869791-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0869791-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023214-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | GRIN3B, OPRM1, GRIN3A | POLB 546/4885ROCK2 3811/4885ROCK1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.